Evidence map›Paper›PMID 38586090›Full record

ArticleAmerican journal of translational research2024

Thorough examination of the potential biological implications of the cuproptosis-related gene LIPT2 in the prognosis and immunotherapy in pan-cancer.

Mi Luo, Abdul Rehman, Soha Haque, Saba Izhar, Fauzia Perveen, Muhammad Haris, Mostafa A Abdel-Maksoud, Ibrahim A Saleh, Naser Zomot, Abdul Malik and 7 more

Abstract read
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Radiolabeling and evaluation ofScientific reports · 2025
    Article
  6. Targeting cuproptosis in liver cancer: Molecular mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mi LuoDepartment of Infectious Disease, The School of Public Health of Nanjing Medical University, The Second Hospital of Nanjing Nanjing 210037, Jiangsu, China.
Abdul RehmanDistrict Blood Bank Sialkot, AIMTH Sialkot, Pakistan.
Soha HaqueDepartment of Pharmacology, Ziauddin University Karachi, Pakistan.
Saba IzharDepartment of Medicine, CMH, Kharian Medical College Kharian, Pakistan.
Fauzia PerveenDepartment of Biochemistry, Liaquat College of Medicine and Dentistry Karachi, Pakistan.
Muhammad HarisDepartment of Anatomy, Nowshera Medical College Nowshera, Khyber Pakhtunkhwa, Pakistan.
Mostafa A Abdel-MaksoudDepartment of Botany and Microbiology, College of Science, King Saud University P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Ibrahim A SalehFaculty of Science, Zarqa University Zarqa 13110, Jordan.
Naser ZomotFaculty of Science, Zarqa University Zarqa 13110, Jordan.
Abdul MalikDepartment of Pharmaceutics, College of Pharmacy, King Saud University Saudi Arabia.
Abdulaziz AlamriDepartment of Biochemistry, College of Science King Saud University Saudi Arabia.
Ahmad S KodousDepartment of Molecular Oncology, Cancer Institute (WIA) 38, Sardar Patel Road, Chennai, P.O. Box 600036, Tamilnadu, India.
Mohammed AufyDepartment of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna Vienna, Austria.
Mohamed Y ZakyUPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh Pittsburgh, PA 15213, USA.
Muhammad ZaeemMolecular Pharmacology Laboratory, Wenzhou Medical University China.
Yasir HameedDepartment of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur Bahawalpur 63100, Pakistan.
Junwei LiDepartment of Infectious Disease, The School of Public Health of Nanjing Medical University, The Second Hospital of Nanjing Nanjing 210037, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo elucidate the expression levels and prognostic value of the Lipoyltransferase 2 (LIPT2) gene in a pan-cancer view. METHODOLOGY: Our study comprehensively investigated the role of LIPT2 in pan-cancer, combining bioinformatics analyses with experimental validations.

resultsAnalysis of LIPT2 mRNA expression across various cancers revealed a significant up-regulation in 18 tumor types and down-regulation in 8 types, indicating its diverse involvement. Prognostic assessment demonstrated a correlation between elevated LIPT2 expression and poorer outcomes in Overall Survival (OS) and Disease-Free Survival (DFS), particularly in Glioblastoma Multiforme (GBM), Liver Hepatocellular Carcinoma (LIHC), and Pheochromocytoma and Paraganglioma (PCPG). Protein expression analysis in GBM, LIHC, and PCPG affirmed a consistent increase in LIPT2 levels compared to normal tissues. Examining the methylation status in GBM, LIHC, and PCPG, we found reduced promoter methylation levels in tumor samples, suggesting a potential influence on LIPT2 function. Genetic mutation analysis using cBioPortal indicated a low mutation frequency (< 2%) in LIPT2 across GBM, LIHC, and PCPG. Immune correlation analysis unveiled a positive association between LIPT2 expression and infiltration levels of immune cells in GBM, LIHC, and PCPG. Single-cell analysis illustrated LIPT2's positive correlation with functional states, including angiogenesis and inflammation. Enrichment analysis identified LIPT2-associated processes and pathways, providing insights into its potential molecular mechanisms. Drug sensitivity analysis demonstrated that elevated LIPT2 expression conferred resistance to multiple compounds, while lower expression increased sensitivity. Finally, RT-qPCR validation in HCC cell lines confirmed the heightened expression of LIPT2 compared to a control cell line, reinforcing the bioinformatics findings.

conclusionOverall, our study highlights LIPT2 as a versatile player in cancer, influencing diverse aspects from molecular processes to clinical outcomes across different cancer types.

Indexed as

biomarkerLIPT2pan-cancerprognosistreatment

Identifiers

PMID38586090
PMCPMC10994786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.